In 237 adults hospitalised with COVID-19, tixagevimab-cilgavimab (AZD7442) did not improve clinical status on day 15 vs placebo (OR 0.93, p=0.81) or later; rehospitalisation to day 456 was more frequent with it (OR 2.04). Mortality and adverse events did not differ.
RCTn = 237
Massonnaud et al. Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in patients hospitalized with COVID-19: long-term results from the DisCoVeRy trial